4 results match your criteria: "From the Veterans Affairs (VA) Medical Center[Affiliation]"
Objectives: The body of large-scale, epidemiological research on electroconvulsive therapy (ECT) in the United States is limited. To address this gap, we assessed demographic, clinical, pharmacological, and mental health treatment history as well as 2-year mortality outcomes associated with ECT use in the largest U.S.
View Article and Find Full Text PDFOpen versus Endovascular Repair of Abdominal Aortic Aneurysm.
N Engl J Med
May 2019
From the Veterans Affairs (VA) Medical Center, Minneapolis (F.A.L.); VA Healthcare System, West Haven, CT (T.C.K., G.R.J.); Edward Hines, Jr. VA Hospital, Hines, IL (K.T.S., Z.H.); Wake Forest Baptist Health, Winston-Salem, NC (J.A.F.); VA Medical Center, East Orange, NJ (F.T.P.); and VA Medical Center, Madison, WI (J.S.M.).
Background: Elective endovascular repair of an abdominal aortic aneurysm results in lower perioperative mortality than traditional open repair, but after 4 years this survival advantage is not seen; in addition, results of two European trials have shown worse long-term outcomes with endovascular repair than with open repair. Long-term results of a study we conducted more than a decade ago to compare endovascular repair with open repair are unknown.
Methods: We randomly assigned patients with asymptomatic abdominal aortic aneurysms to either endovascular repair or open repair of the aneurysm.
Safety of Biologic and Nonbiologic Disease-modifying Antirheumatic Drug Therapy in Veterans with Rheumatoid Arthritis and Hepatitis C Virus Infection.
J Rheumatol
May 2017
From the Veterans Affairs (VA) Medical Center; Department of Medicine, Division of Infectious Diseases, University of Mississippi Medical Center, Jackson, Mississippi; Birmingham VA Medical Center (VAMC); Department of Medicine, Division of Rheumatology, University of Alabama at Birmingham; Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama; VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, Nebraska; Oregon Health Sciences University, Portland, Oregon, USA.
Objective: To examine the effect of disease-modifying antirheumatic drug (DMARD) therapy on hepatotoxicity among patients with rheumatoid arthritis (RA) and hepatitis C virus (HCV) infection.
Methods: We identified biologic and nonbiologic treatment episodes of patients with RA using the 1997-2011 national data from the US Veterans Health Administration. Eligible episodes had HCV infection (defined by detectable HCV RNA) and subsequently initiated a new biologic or nonbiologic DMARD.